Table 1.

Patients retreated with remdesivir

Comorbidities	Age (years)	Gender	Remdesivir treatment	Days of therapy	Days between treatment	Room air saturation at admission (%)	Maximal oxygen requirement	Days of steroid therapy	Hospitalization outcomes
Non-immunosuppressed
asthma, CAD, CKD, HTN	92	male	initial	5	9	93	2 L	10	discharged on RA
			retreatment	5		86	5 L	5
CAD, CHF, COPD, DM, DVT, HL, iron deficiency anaemia, obesity, TIA	77	female	initial	5	14	87	3 L	5	discharged on RA
			retreatment	5		94	2 L	10
Angelman syndrome, chronic aspiration, chronic hypoxic respiratory failure (on oxygen at night), obesity, seizures	40	male	initial	5	10	84	4 L	10	discharged on oxygen
			retreatment	2		88	6 L	5
DM, HTN, hypothyroidism, NHL in remission	55	female	initial	5	106	92	3 L	0	discharged on RA
			retreatment	3		89	RA	1
					139
			retreatmenta	5		90	3 L	6b
CHF, COPD on oxygen, CVA, DM, DVT/PE, HTN, NSTEMI	72	female	initial	5	27	100	MV	8	deceased
			retreatment	2		99	MV	2
Immunosuppressed
bullous pemphigoid on rituximab, CKD, COPD, DM	62	male	initial	3	16	92	2 L	10	discharged home on RA
			retreatment	5		85	HFNC	10b
BOLT, ILD	32	female	initial	10	10	88	2 L	0c	discharged home on oxygen
			retreatment	2		90	1 L	0c
CKD, metastatic colon cancer	48	male	initial	5	15	98	RA	0	deceased
			retreatment	2		100	3 L	0
follicular lymphoma	49	male	initial	5	49	97	4 L	14	discharged home on oxygen
			retreatment	5		98	MV	taper for new HLH
lymphoma, DVT	72	female	initial	2	36	94	RA	2	deceased
			retreatment	5		70	4 L	5
AML, fungal pneumonia, Staphylococcus epidermidis endocarditis	40	male	initial	5	9	89	4 L	11	deceased
			retreatment	5		MV	MV	11
kidney transplant	53	male	initial	4	15	85	3 L	4	deceased
			retreatment	2		50	MV	10
atrial fibrillation, NHL on rituximab, CKD, HTN	84	male	initial	3	20	90	RA	0	discharged on RA
			retreatment	5		88	3 L	5

BOLT, bilateral orthotopic lung transplantation; CAD, coronary artery disease; CHF, chronic heart failure; CKD, chronic kidney disease; CVA, cerebrovascular accident; DM, diabetes mellitus; DVT, deep-vein thrombosis; HFNC, high-flow nasal cannula; HL, hyperlipidaemia; HLH, haemophagocytic lymphohistiocytosis; HTN, hypertension; ILD, interstitial lung disease; MV, mechanical ventilation; NHL, non-Hodgkin’s lymphoma; NSTEMI, non-ST-elevation myocardial infarction; PE, pulmonary embolism; RA, room air; TIA, transient ischaemic attack.

^aPatient received third treatment of remdesivir.

^bPatient received prednisone taper after initial steroid treatment.

^cPatient was on chronic prednisone due to recent transplant status.